ArticleGastroenterology2014
Building bridges and providing transparency to the hepatitis C virus drug approval process.
Marc G Ghany, T Jake Liang
Abstract readEditorial
In one paragraphArticle in Gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
2 authors.
Marc G GhanyNational Institutes of Health, Bethesda, Maryland.
T Jake LiangNational Institutes of Health, Bethesda, Maryland.
Funding
Molecular Approaches To Vaccine Development For Hepatitis CZIADK054503 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI LIANG, T. JAKE · 2009 to 2025
$18.9MTherapy, Vaccine and Model Development in Viral Hepatitis and Liver DiseasesZIADK054505 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI LIANG, T. JAKE · 2009 to 2025
$17.5MNatural History, Therapy and Pathogenesis of Chronic Viral Hepatitis CZIADK075009 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI GHANY, MARC · 2009 to 2025
$7.2MMolecular Approach To Vaccine Development For HepatitisCZ01DK054503 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI LIANG, T. JAKE · 1997 to 2008
$1.0MTRANSGENIC MOUSE MODEL FOR STUDY OF VIRAL HEPATITIS CZ01DK054504 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI LIANG, T. JAKE · 1997 to 2008
$1.0MNatural History, Therapy and Pathogenesis of Chronic Viral Hepatitis CZ01DK075009 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI GHANY, MARC · 2008 to 2008
$378kIntramural NIH HHS Z01 DK054503Intramural NIH HHS Z01 DK054504Intramural NIH HHS Z01 DK075009Intramural NIH HHS Z99 DK999999Intramural NIH HHS ZIA DK054503Intramural NIH HHS ZIA DK054505NIDDK NIH HHS Z01-DK054503NIDDK NIH HHS Z01-DK054504NIDDK NIH HHS Z01-DK075009
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Drug ApprovalAntiviral AgentsClinical Trials as TopicHepatitis C, ChronicHumansSofosbuvirUnited StatesUnited States Food and Drug AdministrationUridine MonophosphateAntiviral AgentsSofosbuvirUridine Monophosphate
Identifiers
PMID25449025
PMCPMC6299446
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390